Picture of AstraZeneca logo

AZN AstraZeneca Income Statement

0.000.00%
gb flag iconLast trade - 00:00
HealthcareConservativeLarge CapNeutral

Annual income statement for AstraZeneca, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue24,38426,61737,41744,35145,811
Cost of Revenue
Gross Profit19,56021,34727,87535,70237,743
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses21,46021,45536,36140,59437,618
Operating Profit2,9245,1621,0563,7578,193
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes1,5483,916-2652,5016,899
Provision for Income Taxes
Net Income After Taxes1,2273,1441153,2935,961
Minority Interest
Net Income Before Extraordinary Items
Net Income1,3353,1961123,2885,955
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income1,3353,1961123,2885,955
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS1.491.892.773.533.41
Dividends per Share